Emalex Biosciences News and Activities

Emalex Biosciences is owned by Paragon.

Paragon is a company listed under the stock ticker KGaA (DE).

Paragon has a direct presence in 3 countries.

They are in:

• Electrical & Electronic Components33%
• Biotechnology33%
• Other33%

Acquisition, funding and merger involving Paragon.

• Teva Pharmaceutical Industries has announced the acquisition of Emalex Biosciences  (posted on April 30 2026).

View the org chart displaying its 24 main executives

Most searched biographies at Emalex Biosciences

• Eric Messner, Chief Executive Officer
• Paul Reinfelds, Senior Vice President of Legal Affairs and General...
• Ken Borgerding, Chief Compliance Officer and Corporate Counsel

Create your alert
to follow the executive moves at Emalex Biosciences.

Paragon has 2,424 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• The new name of EG 427 is Cyllene Therapeutics. (posted on July 10 2026).
• Opthea will change its company name to Ceryvyn Therapeutics on Jul 9, 2026. (posted on July 9 2026).
• Tissium has just announced a $60 Million fundraising (posted on July 8 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Emalex Biosciences

• Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
• Emalex Receives U.S. Patent for Orally Disintegrating Ecopipam Formulation
• First Patient Dosed in Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy
• Press Releases 5 - Emalex Biosciences
• Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study
• Emalex Biosciences Named “Neuroscience Therapeutics Company Of The Year” by BioTech Breakthrough
• Article: Investigational Med for Tourette Syndrome Promising
• Emalex Biosciences Releases Results of 12-Month Open-Label Extension Study for Tourette Syndrome Candidate
• Emalex Biosciences Releases Results of 12-Month Open-Label Extension Study for Tourette Syndrome Candidate
• Press Releases 4 - Emalex Biosciences
• View more press releases Close

Social media about Emalex Biosciences

• Emalex Biosciences on Wikipedia, Google News & Yahoo Finance
• Emalex Biosciences on LinkedIn, X (Twitter) & YouTube